SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration.

Biotechnology

SparingVision

Stéphane Boissel

Marie Uguen

Ryan Klimczak

Hélène Grimm

Mehdi Gasmi

Florence Paliargues

Anne-Sophie Gautron

Dan Chung

Rajiv Gangurde

Stanislas Piot

Florence Lorget

The Finance and Corporate Development team at SparingVision is responsible for strategic financial management, capital allocation, and fostering partnerships to support innovative biotechnology projects. They analyze financial performance, oversee budgeting and forecasting, and ensure compliance while driving corporate growth initiatives and partnerships that enhance the development and commercialization of therapies for blinding inherited retinal diseases.

Finance and Corporate Development

Clinical Advisory and Project Management

Scientific Advisors

Finance and Corporate Development

About

Team members

Other teams at SparingVision

Clinical Advisory and Project Management

Scientific Advisors